Financial runway Seed funding of 1.5M indicates early-stage growth with limited current revenue; opportunity to position Cadex Genomics for strategic partnerships or additional rounds to accelerate clinical studies and IP development.

Clinical expansion Focus on expanding clinical studies and validating the Alibrex blood-based assay positions the company for collaborations with oncology centers, diagnostic labs, and payer discussions around value-based testing.

Targeted audience Product is designed for physicians aiming to identify non-responders to cancer therapy through non-invasive blood tests, enabling sales conversations with academic hospitals, cancer centers, and community oncology practices.

Competitive edge High sensitivity and simple blood draw positioning Cadex Genomics as a less invasive, faster option relative to tissue biopsies, appealing to providers seeking quicker therapy-response insights and patient-friendly workflows.

Market readiness Small company size with lean revenues suggests prioritizing partnerships with larger genomic players or contract research organizations to scale validation, distribution, and reimbursement discussions.